• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Universe Pharmaceuticals Inc.

    2/14/25 5:24:21 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    UNIVERSE PHARMACEUTICALS, INC.

    (Name of Issuer)


    Ordinary Shares, $0.01875 par value

    (Title of Class of Securities)


    G9442G104

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Anson Funds Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Anson Management GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Tony Moore
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Anson Advisors Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ONTARIO, CANADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    FI, CO


    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Amin Nathoo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    G9442G104


    1Names of Reporting Persons

    Moez Kassam
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    782,327.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    782,327.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    782,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    UNIVERSE PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    265 Jingjiu Avenue, Jinggangshan Economic and Tech Dev Zone Ji'an, Jiangxi, China 343100
    Item 2. 
    (a)Name of person filing:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam
    (b)Address or principal business office or, if none, residence:

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore: 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248 For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam: 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3
    (c)Citizenship:

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.
    (d)Title of class of securities:

    Ordinary Shares, $0.01875 par value
    (e)CUSIP No.:

    G9442G104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    To come.
    Item 4.Ownership
    (a)Amount beneficially owned:

    (a) Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 782,327 shares of Ordinary Shares held by the Fund. (b) Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 9.9% of the outstanding shares of Ordinary Shares, which includes shares of Ordinary Shares underlying outstanding warrants (each, a "Warrant," and collectively, the "Warrants") held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam. Each Warrant includes a beneficial ownership limitation. The Warrants may not be exercised to the extent the Reporting Persons would, in the case of some of the Warrants, beneficially own more than 4.99%, and in the case of others, beneficially own more than 9.99% of the outstanding Ordinary Shares. The beneficial ownership set forth herein takes into account the foregoing limitation. This percentage is determined by dividing 782,327 by 7,831,104, which is the sum of: (i) 7,279,184 shares of Ordinary Shares issued and outstanding, as confirmed by the Issuer on February 4, 2025; and (ii) 551,920 the number of shares of Ordinary Shares receivable by the Fund upon exercise of the Warrants. (c) Anson Funds Management LP and Anson Advisors Inc., as the co-investment advisors to the Fund, may direct the vote and disposition of the 782,327 shares of Ordinary Shares held by the Fund. Anson Management GP LLC, as the general partner of Anson Funds Management LP, may direct the vote and disposition of the 782,327 shares of Ordinary Shares held by the Fund. As the principal of Anson Funds Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 782,327 shares of Ordinary Shares held by the Fund. Mr. Nathoo and Mr. Kassam, each as a director of Anson Advisors Inc., may direct the vote and disposition of the 782,327 shares of Ordinary Shares held by the Fund.
    (b)Percent of class:

    See Section 4(a)
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Section 4(a)

     (ii) Shared power to vote or to direct the vote:

    See Section 4(a)

     (iii) Sole power to dispose or to direct the disposition of:

    See Section 4(a)

     (iv) Shared power to dispose or to direct the disposition of:

    See Section 4(a)

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See description regarding the Fund in the introduction, which is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. For Anson Advisors Inc.: By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to portfolio managers and exempt market dealers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Anson Funds Management LP
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore Manager
    Date:02/14/2025
     
    Anson Management GP LLC
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore Manager
    Date:02/14/2025
     
    Tony Moore
     
    Signature:/s/ To come
    Name/Title:To come
    Date:02/14/2025
     
    Anson Advisors Inc.
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo Director
    Date:02/14/2025
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam Director
    Date:02/14/2025
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo
    Date:02/14/2025
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam
    Date:02/14/2025
     
    Amin Nathoo
     
    Signature:/s/ To come
    Name/Title:To come
    Date:02/14/2025
     
    Moez Kassam
     
    Signature:/s/ To come
    Name/Title:To come
    Date:02/14/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement dated February 14, 2025, by and among Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.

    Get the next $UPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

      2/14/23 2:14:41 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

      SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

      2/11/22 8:00:43 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

      SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

      12/28/21 4:10:53 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Universe Pharmaceuticals INC Announces Share Consolidation

      Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

      3/20/25 8:30:00 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

      Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

      2/25/25 4:10:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

      Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the "Delisting Determination"), because the bid price of the Company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the "Rule"). Normally, a company w

      2/3/25 4:10:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    See more
    • Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

      Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

      12/15/21 4:30:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

      SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

      5/15/25 6:07:40 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Universe Pharmaceuticals Inc.

      20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

      4/29/25 4:05:32 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Universe Pharmaceuticals Inc.

      6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

      3/20/25 8:33:28 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care